Trial Profile
Clinical efficacy of 13-valent pneumococal conjugate vaccine (PCV13) for prevention of COPD exacerbations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Nov 2017
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Chronic obstructive pulmonary disease; Pneumococcal infections
- Focus Therapeutic Use
- 16 Nov 2017 New trial record